Next Article in Journal
A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011
Previous Article in Journal
Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
Previous Article in Special Issue
Evolution of Biologics Screening Technologies
Open AccessArticle

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease

Department of Paediatrics, Monash University, Clayton, Victoria 3052, Australia
Department of Gastroenterology, the Royal Children's Hospital, Parkville, Victoria 3052, Australia
Department of Paediatrics, University of Melbourne, Parkville, Victoria 3052, Australia
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(10), 1322-1334;
Received: 2 July 2013 / Revised: 2 October 2013 / Accepted: 9 October 2013 / Published: 16 October 2013
(This article belongs to the Special Issue Biologics)
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn’s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn’s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth. We retrospectively audited patients on maintenance infliximab at a single centre. Data included height and weight, Paediatric Crohn’s Disease Activity Index (PCDAI), and immunomodulator use. 71 children (32% female, mean age 14.4 years) had been commenced on maintenance infliximab before July 2011. 89% had been on immunomodulators concurrently with infliximab. LoR occurred in 20 (28%), with a median time to LoR of 4.31 years. LoR was significantly increased in children who did not enter remission (PCDAI ≤ 10) after induction (p < 0.05). LoR occurred more frequently in the 72% who ceased immunomodulators, but this failed to reach statistical significance (p = 0.300). Height and weight SDS improved significantly on infliximab. Infliximab is a durable long-term therapy for paediatric Crohn’s refractory to conventional therapy. A large-magnitude increase in the rate of loss of response after immunomodulator cessation was not observed. View Full-Text
Keywords: Crohn’s disease; paediatrics; infliximab; immunomodulator; growth Crohn’s disease; paediatrics; infliximab; immunomodulator; growth
Show Figures

Figure 1

MDPI and ACS Style

Gouldthorpe, O.; Catto-Smith, A.G.; Alex, G.; Simpson, D. Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease. Pharmaceuticals 2013, 6, 1322-1334.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop